Claims

1. Use of an effective amount of sydnocarb, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating a dyskinesia in a human.

2. Use according to claim 1, wherein the medicament is for oral administration in a tablet, pill, or capsule.

3. Use according to any one of claims 1 to 2, wherein 0.01 mg to 70 mg per kg body weight of sydnocarb is to be administered.


4. Use according to any one of claims 1 to 3, further comprising an additional therapeutic agent of L-Dopa.

5. Use according to claim 4, wherein the sydnocarb, or a pharmaceutically acceptable salt thereof, and L-Dopa are present within different pharmaceutical compositions, and the pharmaceutical composition comprising sydnocarb, or pharmaceutically acceptable salt thereof, is to be administered to the human prior to, concurrently with, or after the pharmaceutical composition comprising L-Dopa.


6. Use according to any one of claims 1 to 5, wherein the dyskinesia is levodopa-induced dyskinesia, chronic or tardive dyskinesia, or orofacial dyskinesia.

7. Use according to claim 6, wherein the levodopa-induced dyskinesia is off-period dystonia, diphasic dyskinesia, or peak-dose dyskinesia.


8. Use according to any one of claims 1 to 7, wherein the sydnocarb comprises the formula




(Ia-1),



(Ib-1),



(Ic-1), or




(Id-1),


or a pharmaceutically acceptable salt thereof, wherein: U is C; W is H; Y is H; X is O; Z is O; Q is phenyl; R^1 is H and r is 1; R^2 and R^3 are H and n is 1; R^4 and R^5 are H and p is 1; R^7 is H; and R^8 is H.

9. A pharmaceutical composition comprising sydnocarb, L-Dopa, and a pharmaceutically acceptable carrier.


10. The pharmaceutical composition of claim 9, wherein the sydnocarb comprises the formula




(Ia-1),



(Ib-1),



(Ic-1), or



(Id-1),

or a pharmaceutically acceptable salt thereof, wherein: U is C; W is H; Y is H; X is O; Z is O; Q is phenyl; R_1 is H and r is 1; R_2 and R_3 are H and n is 1; R_4 and R_5 are H and p is 1; R_7 is H; and R_8 is H.

5